Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

Executive Summary

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

You may also be interested in...



AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged

AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.

CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics

The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”

CMS Targeting LTC Facility Overprescribing, Citing Antipsychotics

The Centers for Medicare and Medicaid Services is proposing a new Medicare requirement that consulting pharmacists serving long-term care facilities maintain independence from the facility to help avoid drug “overprescribing and overutilization.”

Related Content

Topics

UsernamePublicRestriction

Register

PS052171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel